Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours Read more
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Read more
Sandoz announces agreement to acquire CIMERLI business from Coherus, strengthening position in US market Read more
FDA Grants Full Approval for BALVERSA to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations Read more
European Commission approves Roche’s Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types Read more
FDA Approves Takeda’s HYQVIA as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Read more
Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype Read more
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer Read more
Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies Read more